Abstract
What is the difference between biomarker and pharmacogenomic (PGx) research? How is this research conducted and what value does it have for patient care? These are just some of the questions that institutional review board and independent ethics committee (IRB/IEC) members may ask themselves when encountering PGx or biomarker research in a clinical protocol. This article summarizes findings from an Industry Pharmacogenomics Working Group survey of IRB/IEC members on related topics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
